News

 

At AseBio, we follow the latest news in the biotechnology sector and pass the highlights on to you. You can use the search engine to find news articles we’ve written, contributed by our members or from other stakeholders in the sector. And they are also organised into categories to help you find the topics you’re interested in easily.

Search engine
jjj
Preparation is key: brief checklist how to bring IVD MD into compliance with EU IVDR
El IVDR evolucionó a partir de la IVDD para establecer un “marco más sólido, transparente,…
Partners - NAMSA
edificio oryzon
ORYZON to present new clinical data and corporate updates at international conferences in June and July
Healthcare
Emerging Biotech Company Showcase organizado por NewYorkBIO y la Bolsa de Nueva York Spring…
Partners - Oryzon Genomics
Moirai Biodesign Team
Moirai Biodesign creates an innovative synthetic RNA design software
Healthcare · Drug discovery · Advanced therapies
Moirai Biodesign – a biotech startup located at the Barcelona Scientific Park, pioneer in the…
Partners - Parc Científic de Barcelona
foto oryzon
ORYZON announces FDA approval of IND for PORTICO, a Phase IIb trial with vafidemstat in Borderline Personality Disorder
Healthcare
Recruitment ongoing in Europe. Primary objectives: to assess the effect of vafidemstat to…
Partners - Oryzon Genomics
foto oryzon 2
ORYZON presents iadademstat ALICE 30-month data at EHA-2021, confirming positive and robust efficacy in combination with azacitidine in AML
Healthcare
Robust signals of clinical efficacy, with ORR of 83%, of which 67% are CR/CRi and five…
Partners - Oryzon Genomics
genesis biomed
Algorithms and Image Biomarkers. Radiomics as another piece of precision oncology
Personalized medicine
Radiomics is revolutionising medical image interpretation
Partners - GENESIS Biomed
lim global
LIM Global, Digital transformation and rebranding by eMascaró
The objectives were clear: communicate the brand's values, encourage customer attraction, entice…
Partners - LIM Global
owl
OWL Metabolomics and Sagimet Biosciences closed an agreement to use OWL´s services in Sagimet´s Phase 2b FASCINATE-2 Clinical Trial
Healthcare
In a recent Phase 2a trial, TVB-2640 improved serum biomarkers of liver injury in patients with…
Ysios Capital anuncia la salida a bolsa en el NASDAQ de su compañía participada CVRx, Inc.
Ysios Capital closes its third fund at €216 million ($260 million)
Ysios BioFund 3 (YBF 3) is the firm’s largest fund to date. To invest in up to 15 companies in…
Partners - Ysios Capital Partners